Nothing Special   »   [go: up one dir, main page]

LV10097B - New pharmacologically active catechol derivatives - Google Patents

New pharmacologically active catechol derivatives Download PDF

Info

Publication number
LV10097B
LV10097B LVP-92-185A LV920185A LV10097B LV 10097 B LV10097 B LV 10097B LV 920185 A LV920185 A LV 920185A LV 10097 B LV10097 B LV 10097B
Authority
LV
Latvia
Prior art keywords
formula
dihydroxy
group
compound
sulfur
Prior art date
Application number
LVP-92-185A
Other languages
English (en)
Other versions
LV10097A (lv
Inventor
Reijo Johannes B Ckstrim
Erkki Juhani Honkanen
Inge-Britt Yvonne Linden
Erkki Aarne Olavi Nissinen
Aino Kyllikki Pippuri
Pentti Pohto
Tapio Korkolainen
Original Assignee
Orion Yhtym Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909009565A external-priority patent/GB9009565D0/en
Priority claimed from GB919101563A external-priority patent/GB9101563D0/en
Application filed by Orion Yhtym Oy filed Critical Orion Yhtym Oy
Publication of LV10097A publication Critical patent/LV10097A/lv
Publication of LV10097B publication Critical patent/LV10097B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (7)

  1. LV 10097 JAUNI FARMACEITISKI AKTĪVI KATEHOLA ATVASINĀJUMI PATENTA FORMULA 1. Savienojums ar vispārēju formulu I
    *1 HO kur Ri ir elektronegatīvs aizvietotājs, tāds kā nitrogrupa, halogēns vai cianogrupa un R2 ir grupa, ko izvēlas no
    un
    kurā Χι, Χ2 , Y un Z neatkarīgi ir skābeklis, sērs vai NR, kurā R ir ūdeņradis, alkil-, cikloalkil-, aralkil- vai arilgrupa, vai to farmaceitiski piemēroti sāļi vai ēsteri. 2
  2. 2. Savienojums, saskaņā ar 1. punktu, kur savienojumā ar formulu I, R2 ir grupa ar formulu la Ϊ
    kurā Xi un X2 abas ir NR, kur R ir ūdeņradis vai alkils, Y ir skābeklis vai sērs un Z ir skābeklis vai sērs.
  3. 3. Savienojums, saskaņā ar 2. punktu, kur savienojums ir izvēlēts no grupas, kas sastāv no 4- [(3,4-dihidroksi-5-nitrofenil)metiliden]-2-tiokso-imidazolidin- 5- ona, 4-[(3,4-dihidroksi-5-hlorfenil)metiliden]-2-tiokso-imidazolidin-5-ona un 4-[(3,4-dihidroksi-5-nitrofenil)metiliden]-2,5*imidazolidindiona.
  4. 4. Savienojums, saskaņā ar 1. punktu, kur savienojumā ar formulu I, R2 ir grupa ar formulu la Y
    kurā Χι, Y, un Z neatkarīgi ir skābeklis vai sērs un X2 ir NR, kurā R ir ūdeņradis vai alkils.
  5. 5. Savienojums, saskaņā ar 1. punktu, kur savienojumā ar formulu I, R2 ir grupa ar formulu la, 5 LV 10097
    kura Xl un Z neatkarīgi ir skābeklis vai sērs un Y un Χ2 ir NR, kur R ir ūdeņradis. 10
  6. 6. Savienojums, saskaņā ar 1. punktu, kur savienojumā ar formulu I, R2 ir grupa ar formulu la, kurā R2 ir 15
    20 kur Y ir skābeklis vai sērs, Xi ir NR, kur R ir ūdeņradis vai alkils. 25
  7. 7. Metode savienojuma ar formulu I iegūšanai 30 I, kur Ri ir elektronegatīvs aizvietotājs, tāds kā nitrogrupa, halogēns vai cianogrupa un R2 grupa, kas izvēlēta no: 35 4
    un
    kur Χχ , X2 , Y un Z neatkarīgi ir skābeklis, sērs vai NR, kur R ir ūdeņradis, alkil-, cikloalkil-, aralkil- vai arilgrupas, kas satur aldehīda ar formulu II kondensētu HO^_ HO-/qVcho II» *1 kur Ri ir kā definēts iepriekš, ar vienu no savienojumiem ar formulām III vai IV, kurā ir aktīva metilengrupa, Y
    * 0 LV 10097 kur Χι, Χ2 , Y un Z ir kā definēts iepriekš, dodot savienojumu ar formulu la, kur pēc tam oglekļa-oglekļa dubultsaite savienojumā la var tikt reducēta, dodot savienojumu Ib saskaņā ar izgudrojumu.
LVP-92-185A 1990-04-27 1992-10-26 New pharmacologically active catechol derivatives LV10097B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909009565A GB9009565D0 (en) 1990-04-27 1990-04-27 New pharmacologically active catechol derivatives
GB919101563A GB9101563D0 (en) 1991-01-24 1991-01-24 New pharmacologically active catechol derivatives
PCT/FI1991/000124 WO1991017151A1 (en) 1990-04-27 1991-04-26 New pharmacologically active catechol derivatives

Publications (2)

Publication Number Publication Date
LV10097A LV10097A (lv) 1994-05-10
LV10097B true LV10097B (en) 1995-02-20

Family

ID=26297011

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-92-185A LV10097B (en) 1990-04-27 1992-10-26 New pharmacologically active catechol derivatives

Country Status (17)

Country Link
US (3) US5362733A (lv)
EP (1) EP0526598B1 (lv)
JP (1) JP2972377B2 (lv)
KR (1) KR100207144B1 (lv)
AT (1) ATE146462T1 (lv)
AU (1) AU646464B2 (lv)
CA (1) CA2080917C (lv)
DE (1) DE69123738T2 (lv)
FI (1) FI95129C (lv)
HU (1) HU214872B (lv)
IE (1) IE911430A1 (lv)
LT (1) LT3137B (lv)
LV (1) LV10097B (lv)
NO (1) NO301928B1 (lv)
PL (1) PL166269B1 (lv)
PT (1) PT97507B (lv)
WO (1) WO1991017151A1 (lv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2210566A1 (en) * 1995-01-23 1996-08-01 Eli Lilly And Company Method for treating multiple sclerosis
AU5577498A (en) * 1997-01-31 1998-08-25 Shionogi & Co., Ltd. Compounds having metalloprotease inhibitory activity
WO1998039967A1 (en) * 1997-03-12 1998-09-17 The General Hospital Corporation A method for treating or preventing alzheimer's disease
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
AU7961800A (en) * 1999-10-28 2001-05-08 Kyowa Hakko Kogyo Co. Ltd. Thiazolidinedione derivatives
WO2002053155A1 (en) * 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
JP4425628B2 (ja) * 2001-07-23 2010-03-03 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 細胞保護化合物、薬学的処方物および美容用処方物、ならびに方法
US6679051B1 (en) * 2002-07-31 2004-01-20 Ford Global Technologies, Llc Diesel engine system for use with emission control device
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
PL1689726T3 (pl) 2003-11-21 2011-05-31 Actelion Pharmaceuticals Ltd Pochodne 5-(benz-(z)-ylideno)tiazolidyn-4-onu jako środki immunosupresyjne
WO2007098010A2 (en) * 2006-02-17 2007-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Improved low molecular weight myc-max inhibitors
EP2489662B1 (en) 2006-11-23 2014-08-06 Actelion Pharmaceuticals Ltd. Intermediates of a new process for the preparation of 5-benzylidene-2-alkylimino-3-phenylthiazolidin-4-one derivatives
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
FR2919608B1 (fr) * 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
CA2734991A1 (en) * 2008-07-23 2010-01-28 Massachusetts Institute Of Technology Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
KR101411838B1 (ko) 2011-02-09 2014-06-27 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
PL2734510T4 (pl) 2011-07-22 2019-05-31 Massachusetts Inst Technology Aktywatory deacetylaz histonowych klasy I (HDAC) i ich zastosowania
ES2795105T3 (es) 2012-08-17 2020-11-20 Actelion Pharmaceuticals Ltd Proceso para la preparación de (2Z,5Z)-5-(3-cloro-4-((R)-2,3-dihidroxipropoxi)bencilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona y producto intermedio usado en dicho proceso
AU2017246413B2 (en) * 2016-04-05 2021-09-23 Immune Sensor, Llc cGAS antagonist compounds
WO2022163843A1 (ja) * 2021-02-01 2022-08-04 国立大学法人徳島大学 Ｐｉｍ２阻害剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1038050B (de) * 1955-11-17 1958-09-04 Farmaceutici Italia S A Soc Verfahren zur Herstellung von 5-(3', 4'-Dioxybenzyliden)-Derivaten heterocyclischer Verbindungen
US4264617A (en) * 1972-06-16 1981-04-28 Canada Packers, Limited Antiviral 5-(substituted benzal) hydantoins
GB1439318A (en) * 1972-06-16 1976-06-16 Canada Packers Ltd 5-substituted benzal- hydantoins derivatives
US4013770A (en) * 1972-06-16 1977-03-22 Canada Packers Limited Antiviral 5-(substituted benzal) hydantoins
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
DE3013626C2 (de) * 1980-04-09 1985-06-27 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Arylidenhydantoinen (A)
DE3013647C2 (de) * 1980-04-09 1985-07-11 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Arylidenhydantoinen (B)
JPS60233063A (ja) * 1984-05-02 1985-11-19 Showa Denko Kk ５−ベンジリデンヒダントインの製造法
US4650876A (en) * 1984-08-17 1987-03-17 Stauffer Chemical Company Hydrogenation of substituted, unsaturated hydantoins to substituted, saturated hydantoins
US4582903A (en) * 1984-08-17 1986-04-15 Stauffer Chemical Company Synthesis of unsaturated hydantoins with an inexpensive catalyst
CA1285572C (en) * 1985-08-09 1991-07-02 Jill Ann Panetta Di-t-butylphenol compounds
US5208250A (en) * 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
US5306822A (en) * 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
GB8911073D0 (en) * 1989-05-15 1989-06-28 Fujisawa Pharmaceutical Co New benzofuran derivatives,a process for the preparation thereof and pharmaceutical composition comprising the same
JPH1052765A (ja) 1996-08-09 1998-02-24 Sukematsu Iwashita 鉄筋材の圧接装置

Also Published As

Publication number Publication date
NO301928B1 (no) 1997-12-29
LTIP227A (lt) 1994-08-25
JPH05331148A (ja) 1993-12-14
PT97507A (pt) 1992-01-31
NO924132L (no) 1992-12-23
CA2080917C (en) 2001-06-12
US5362733A (en) 1994-11-08
CA2080917A1 (en) 1991-10-28
US5614541A (en) 1997-03-25
PT97507B (pt) 1998-08-31
FI95129C (fi) 1995-12-27
FI924838A (fi) 1992-10-23
ATE146462T1 (de) 1997-01-15
EP0526598A1 (en) 1993-02-10
DE69123738D1 (en) 1997-01-30
DE69123738T2 (de) 1997-07-03
LT3137B (en) 1995-01-31
HU9203369D0 (en) 1993-01-28
LV10097A (lv) 1994-05-10
FI924838A0 (fi) 1992-10-23
EP0526598B1 (en) 1996-12-18
HUT65662A (en) 1994-07-28
HU214872B (hu) 1998-07-28
KR100207144B1 (en) 1999-07-15
FI95129B (fi) 1995-09-15
KR930700468A (ko) 1993-03-15
AU646464B2 (en) 1994-02-24
JP2972377B2 (ja) 1999-11-08
PL166269B1 (pl) 1995-04-28
AU7761891A (en) 1991-11-27
NO924132D0 (no) 1992-10-26
US5889037A (en) 1999-03-30
IE911430A1 (en) 1991-11-06
WO1991017151A1 (en) 1991-11-14

Similar Documents

Publication Publication Date Title
LV10097B (en) New pharmacologically active catechol derivatives
IE83426B1 (en) New pharmacologically active catechol derivatives
CA2073981C (en) 2-arylthiazole derivatives and pharmaceutical composition thereof
US4552874A (en) Pyrazolooxazines, pyrazolothiazines, and pryazoloquinolines and their use as medicaments
US5336677A (en) Substituted aminopyrimidines as antihypertensives
US5008266A (en) 4(3H)-quinazolinone derivatives and pharmaceutical compositions
HU208826B (en) Process for producing pteridin-4-/3h/-one derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
JPH0629270B2 (ja) Ｎ―置換２―アミノチアゾール類及び治療用組成物
JP3086692B2 (ja) 抗炎症剤としてのフエナメート１，３，４‐チアジアゾール類および１，３，４‐オキサジアゾール類
KR100191385B1 (ko) 치환된 피리미딘 유도체,이의 제조방법 및 약제로서의 이의 용도
US6121303A (en) Pharmacologically active catechol derivatives
US4397849A (en) Benzothiazine derivatives
RU2096407C1 (ru) Производные катехола и способ их получения
CA2377230C (en) Benzimidazole compounds and medicaments comprising the same
HRP921248A2 (en) New pharmacologically active catehol derivatives
BG61646B1 (bg) фармакологично активни катехинови съединения, метод за получаването им и тяхното използване
SK279658B6 (sk) Katecholová zlúčenina, spôsob jej prípravy, farmac
IE54121B1 (en) Pharmaceutically active imidazolecarboxylic acid derivatives
RO109841B1 (ro) Derivați de catechol și procedeu de preparare a acestora
KR800001636B1 (ko) 티아졸리딘 화합물의 제조방법
AU623659B2 (en) New benzazole derivatives, processes for their preparation and pharmaceutical preparations containing such compounds and use thereof